Will the FDA change how it vets drugs following the Alzheimer’s debacle?

Max Kozlov

Nature, 2022, vol. 605, issue 7911, 600-601

Abstract: The accelerated approval of aducanumab has triggered US lawmakers to push for more oversight from the agency.

Keywords: Policy; Medical research; Health care (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-022-01316-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:605:y:2022:i:7911:d:10.1038_d41586-022-01316-8

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-022-01316-8

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().